source
- Ipsen to acquire blood-cancer specialist Kartos Therapeutics for $450 million upfrontIpsen announced it will purchase Kartos Therapeutics, a company focused on blood cancers. The transaction includes a $450 million cash payment at closing, with the possibility of up to $1.75 billi…
- BioCryst to shut internal drug discovery and close Alabama research siteBioCryst Pharmaceuticals announced it is winding down its internal drug discovery efforts. The company said it will seek future programs through external collaborations rather than in‑house resear…